"Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that ... this potential treatment could be a critical tool to help quell the pandemic," Bourla said.
Pfizer tested the antiviral combination treatment, which is given together with an older antiviral called ritonavir, against a man-made version of a key protein that Omicron uses to reproduce itself.
The U.S. Food and Drug Administration (FDA) is expected to soon rule on whether to authorize the pill, as well as Merck’s molnupiravir, which was submitted to regulators several weeks earlier. If granted, the drug would be the first treatment against the CCP virus that Americans could pick up at a pharmacy and take at home.
Dr. Anthony Fauci, chief medical adviser to the Biden administration, said it is "good news" that after Pfizer released final results, the data remained "just as good, if not better" compared to its interim analysis.
"That's really good news," Fauci said. "So, they're going to be submitting that to the FDA and hopefully we'll get some action on that soon," he added.
"If authorized by the FDA we may soon have pills that treat the virus in those who become infected," Biden said. "We’ve already secured millions of doses. The therapy would be another tool in our toolbox to protect people from the worst outcomes of COVID."